A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 30, 2026

Primary Completion Date

January 30, 2029

Study Completion Date

January 30, 2029

Conditions
Glioma
Interventions
BIOLOGICAL

L19TNF

1 cycle of TNF before resection and 6 cycles after surgery

BIOLOGICAL

L19TNF and TMZ

6 cycles of 28 days with L19TNF and TMZ

BIOLOGICAL

L19TNF and CCNU

6 cycles of 6 weeks of L19TNF and CCNU every 6 weeks

BIOLOGICAL

L19TNF monotherapy

6 cycles of 6 weeks with L19TNF

BIOLOGICAL

L19TNF and TMZ in recurrent astrocytoma

6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).

BIOLOGICAL

L19TNF and CCNU in recurrent astrocytoma

6 cycles of 6 weeks of L19TNF (D1, D3, D5, D22, D24 and D26) and CCNU (D1) every 6 weeks

BIOLOGICAL

L19TNF monothery in recurrent oligodendroglioma

6 cycles of 6 weeks with L19TNF

All Listed Sponsors
lead

Philogen S.p.A.

INDUSTRY